Results 101 to 110 of about 1,701 (184)

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. [PDF]

J Med Virol
Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M.   +11 more
europepmc   +1 more source

The capsid revolution.

Lenacapavir, targeting the HIV-1 capsid, is the first-in-class antiretroviral drug recently approved for clinical use. The development of Lenacapavir is attributed to the remarkable progress in our understanding of the capsid protein made during the last
Ariberto Fassati (151654), Ian A Taylor (8117153)   +1 more
core   +1 more source

Cost-effectiveness of lenacapavir for PrEP in Africa

The Lancet HIV
Davey, Dvora Joseph, Jamieson, Lise
openaire   +4 more sources

PP 5.2 – 00072 Simulations for Once Weekly Dosing of Oral Lenacapavir

Journal of Virus Eradication, 2022
N. Shaik, H. Zhang, S. Girish, M. Rhee, R. Palaparthy, A. Karimzadeh, R. Singh   +6 more
doaj   +1 more source

Lenacapavir Use in France: A National, Observational Study (LENAddOn). [PDF]

Open Forum Infect Dis
Ghosn J, Pourcher V, Allavena C, Hocqueloux L, Lacombe K, Cua E, Bonnet F, Duvivier C, Makinson A, Jacomet C, Lascoux C, Viard JP, Robineau O, Hentzien M, Teicher E, Pialoux G, Abgrall S, Cazanave C, Cabié A, Dudoit Y, Peytavin G, Barrière G, Dunn K, Marcelin AG, Assoumou L, Palich R, LENAddOn Study Group, LENAddOn Study Group .   +27 more
europepmc   +1 more source

Cost-effectiveness of lenacapavir versus tenofovir disoproxil fumarate plus emtricitabine for pre-exposure prophylaxis to prevent HIV-1 transmission in gay, bisexual, and other men who have sex with men in Spain. [PDF]

Lancet Reg Health Eur
Wikman-Jorgensen PE, Iniesta C, Ruiz-Algueró M, Estrada V, Pulido F, Perez-Molina JA, Llenas-García J.   +6 more
europepmc   +1 more source

Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis. [PDF]

Adv Ther
Hawkins N, Hazra A, Brizzi M, Thompson J, Grove R, Sieverding M, Budnik P, Scherzer J, Danchenko N, Anderson SJ, Dupont-Benjamin L.   +10 more
europepmc   +1 more source

Commentary on PURPOSE-1 and PURPOSE-2 trials of lenacapavir: a breakthrough in HIV prevention. [PDF]

Ann Med Surg (Lond)
Idrees M, Iftikhar H, Sohail F, Jadoon M, Khan MH.   +4 more
europepmc   +1 more source

The Delivery Disconnect: Why We Could Not Model the Impact of Foreign Aid Reductions on Vertical HIV Transmission and What Remains Evident About Strategic Priorities. [PDF]

J Int AIDS Soc
Bilinski A, Ciaranello A, Ramaswamy A, Walters M, Webb K, Imai-Eaton JW.   +5 more
europepmc   +1 more source

New therapy for HIV infections: Lenacapavir

reservedIl virus dell’immunodeficienza umana HIV è l’agente responsabile della sindrome da immunodeficienza acquisita (AIDS). Da quando è stata riconosciuta, negli anni ’80, ad oggi ha causato più di 40 milioni di decessi. L’infezione da HIV determina
BERDONDINI, LAURA
core